Article
Medicine, General & Internal
Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O'Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jae H. Park, Marion Subklewe, Mehrdad Abedi, Monique C. Minnema, William G. Wierda, Daniel J. DeAngelo, Patrick Stiff, Deepa Jeyakumar, Chaoling Feng, Jinghui Dong, Tong Shen, Francesca Milletti, John M. Rossi, Remus Vezan, Behzad Kharabi Masouleh, Roch Houot
Summary: KTE-X19 demonstrated a high rate of complete remission or complete remission with incomplete haematological recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Median overall survival was not reached in responding patients, and the therapy showed a manageable safety profile. These findings suggest that KTE-X19 has the potential to provide long-term clinical benefit to these patients.
Review
Health Care Sciences & Services
Ross Salvaris, Pasquale Luke Fedele
Summary: In the past decade, significant progress has been made in understanding the genetic mutations underlying acute lymphoblastic leukemia (ALL), leading to the discovery of driver mutations with prognostic implications. Targeted therapies and immunotherapies have shown promise in treating different subtypes of ALL, but come with unique toxicities and sequencing considerations. Advances in T-ALL have been slower compared to B-ALL, but promising results have been seen with agents targeting T cell antigens like nelarabine and CAR T cell therapy.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Anthony Moorman, Ellie Butler, Emilio Barretta, Amy A. Kirkwood, Claire Schwab, Thomas Creasey, Daniel A. Leongamornlert, Elli Papaemmanuil, Pip Patrick, Laura Clifton-Hadley, Bela Patel, Tobias F. Menne, Andrew K. McMillan, Christine J. Harrison, Clare J. Rowntree, David Marks, Adele K. Fielding, Eleanor J. Ward, Katie Twentyman, Amir Enshaei
Summary: Chromosomal abnormalities have a significant prognostic impact on patients with B-cell precursor ALL, with specific abnormalities like KMT2A-AFF1, complex karyotype, and low hypodiploidy/near-triploidy associated with poor outcomes. Patients with BCR-ABL1 have similar outcomes to others, while JAK-STAT abnormalities are linked to a high relapse rate of 56%.
Article
Hematology
Zaid H. Abdel Rahman, Ricardo D. Parrondo, Michael G. Heckman, Mikolaj Wieczorek, Kevin C. Miller, Hassan Alkhateeb, Lisa Z. Sproat, Hemant Murthy, William J. Hogan, Mohamed A. Kharfan-Dabaja, Jess F. Peterson, Linda B. Baughn, Nicole Hoppman, Mark R. Litzow, Rhett P. Ketterling, Patricia T. Greipp, James M. Foran
Summary: Patients with therapy-related acute lymphoblastic leukaemia (tr-ALL) differed significantly from de novo ALL patients in terms of age, gender, cytogenetic abnormalities, etc. Patients with tr-ALL were less likely to achieve complete remission, but had similar overall survival rates after diagnosis and allogeneic hematopoietic cell transplantation.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Medicine, General & Internal
J. Feng, Frankie W. T. Cheng, Alan K. S. Chiang, Grace K. S. Lam, Terry T. W. Chow, S. Y. Ha, C. W. Luk, C. H. Li, S. C. Ling, P. W. Yau, Karin K. H. Ho, Alex W. K. Leung, Natalie P. H. Chan, Margaret H. L. Ng, C. K. Li
Summary: Compared with young children with acute lymphoblastic leukaemia (ALL), adolescents with ALL have less favourable genetic features and poorer response to initial treatment, leading to lower survival rates primarily due to a higher incidence of treatment-related death (TRD).
HONG KONG MEDICAL JOURNAL
(2022)
Article
Oncology
Hye Won Kook, Jin Ju Kim, Mi Ri Park, Ji Eun Jang, Yoo Hong Min, Seung-Tae Lee, Saeam Shin, June-Won Cheong
Summary: This study compared the clinicopathological characteristics and outcomes of patients with therapy-related acute lymphoblastic leukemia (tr-ALL) and de novo ALL (dn-ALL). The results showed some differences in gene mutations, but no significant differences were found in overall survival and progression-free survival between the two groups.
Article
Oncology
Hui Yu, Juan Han, Xiaoyan Wu, Yining Qiu, Jiawei Xu, Jinjin Hao, Yun Peng, Runming Jin, Fen Zhou
Summary: This retrospective study aimed to assess the changes in thyroid hormone levels during induction chemotherapy for acute lymphoblastic leukemia (ALL) in children and investigate the prognostic value of hypothyroidism in ALL. The results showed that hypothyroidism was commonly present during induction remission in ALL children, and it was associated with chemotherapy drugs and severe infections. Hypothyroidism was found to be a predictor of poor prognosis in childhood ALL.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
David O'Connor, Jonas Demeulemeester, Lucia Conde, Amy Kirkwood, Kent Fung, Foteini Papaleonidopoulou, Gianna Bloye, Nadine Farah, Sunniyat Rahman, Jeremy Hancock, Caroline Bateman, Sarah Inglott, Jon Mee, Javier Herrero, Peter Van Loo, Anthony V. Moorman, Ajay Vora, Marc R. Mansour
Summary: Failure to respond to induction chemotherapy is associated with poor outcome in childhood acute lymphoblastic leukemia (ALL) , especially in T-cell ALL (T-ALL). This study aimed to investigate clinical and genetic factors that influence outcome in T-ALL induction failure (IF). The study found that IF occurred in 10.3% of cases, with increasing age being a risk factor. The overall survival rate was significantly lower in IF patients compared to responsive patients. Genomic profiling revealed that TAL1 noncoding mutations were associated with poor prognosis.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Hematology
Fadi G. Haddad, Hampig Raphael Kourie, Khalil Saleh
Summary: Chemotherapy-free regimens are changing the way Philadelphia chromosome-positive acute lymphoblastic leukaemia is treated. The combination of dasatinib and prednisone is found to be effective for induction and early consolidation. Survival rates are improved in patients who undergo allogeneic stem cell transplantation.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Ioannis Peppas, Anthony M. Ford, Caroline L. Furness, Mel F. Greaves
Summary: Children with newly diagnosed acute lymphoblastic leukaemia may have a delayed maturation of the gut microbiome compared with healthy children, which could be associated with early-life epidemiological factors and contribute to the risk of transformation of preleukaemic clones in response to common infectious triggers.
NATURE REVIEWS CANCER
(2023)
Article
Medicine, General & Internal
Courtney D. Dinardo, Harry P. Erba, Sylvie D. Freeman, Andrew H. Wei
Summary: Progress in acute myeloid leukaemia treatment has seen significant improvements in scientific understanding, prognostication tools, risk assessments, and incorporation of measurable residual disease into risk assessments. Recent updates in classification and recommendations by organizations such as WHO, ICC, and European LeukemiaNet have provided enhanced guidance for prognostic stratification and treatment response assessment. There have also been advancements in treatment options, leading to improved outcomes for both newly diagnosed and relapsed patients.
Article
Hematology
Nianci Chen, Jiajia Pan, Yile Zhou, Liping Mao, Yinjun Lou, Jiejing Qian, Gaixiang Xu, Juying Wei, De Zhou, Lihong Shou, Li Huang, Minchao Yan, Hui Zeng, Cuihua Fan, Gongqiang Wu, Weiying Feng, Hongyan Tong, Jie Jin, Huafeng Wang
Summary: This retrospective analysis investigated the efficacy and safety of different gilteritinib-based combination therapies in relapsed/refractory FLT3-mutated AML patients. The study found that gilteritinib plus hypomethylating agent and venetoclax combination therapy showed higher response rates and may serve as an effective bridge to transplantation.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Cell Biology
Yingchi Zhang, Shicheng Wang, Jingliao Zhang, Chao Liu, Xinqi Li, Wenbo Guo, Yongjuan Duan, Xiaoyan Chen, Suyu Zong, Jiarui Zheng, Yixuan Wu, Xiaoli Chen, Xuelian Cheng, Yanxia Chang, Yue Wang, Feng Ding, Wenyu Yang, Xiaojuan Chen, Ye Guo, Li Zhang, Yumei Chen, Yao Zou, Xiaofan Zhu, Jin Gu, Tao Cheng
Summary: In this study, Zhang et al. used single-cell transcriptomics and B-cell receptor sequencing to analyze the transcriptomic profiles of B-cell acute lymphoblastic leukaemia cells at diagnosis, residual, and relapse stages. They found that the hypoxia pathway could be a potential target for residual leukaemia cells.
NATURE CELL BIOLOGY
(2022)
Article
Hematology
Hasmukh Jain, Manju Sengar, Vasu Babu Goli, Jayashree Thorat, Prashant Tembhare, Dhanlaxmi Shetty, V. N. Avinash Bonda, Lingaraj Nayak, P. G. Subramanian, Bhausaheb Bagal, Nikhil Patkar, Neha Sharma, Himanshi Gupta, Sumeet Gujral
Summary: CD20 expression in precursor B-cell acute lymphoblastic leukemia is associated with poor outcomes, but the combination of bortezomib and rituximab with a pediatric-inspired regimen during induction therapy has shown increased MRD-negative rates in newly diagnosed adolescents and adults. Overall survival and event-free survival rates were promising, with manageable toxicity, suggesting that this combination could be effective in de novo CD20(+) Philadelphia-negative precursor B-ALL.
Article
Medicine, General & Internal
Liv Andres-Jensen, Mette Tiedemann Skipper, Kristian Mielke Christensen, Pia Hedegaard Johnsen, Katrine Aagaard Myhr, Martin Kaj Fridh, Kathrine Grell, A. M. L. Pedersen, Sune Leisgaard Morck Rubak, Martin Ballegaard, Arne Horlyck, Rikke Beck Jensen, Trine-Lise Lambine, Kim Gjerum Nielsen, Ruta Tuckuviene, Peder Skov Wehner, Birgitte Klug Albertsen, Kjeld Schmiegelow, Thomas Leth Frandsen
Summary: This study aims to establish a Nordic, national childhood ALL survivor cohort to investigate the somatic and psychosocial treatment-related burden and associated risk factors. Primary endpoints include the cumulative incidence and burden of 197 health conditions, while secondary endpoints focus on organ-specific outcomes and psychosocial outcomes.
Article
Oncology
Toma S. Omofoye, Anganile Kalinga, Ramapriya Ganti, Frank J. Minja, Timothy B. Rooney
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Prarthna V. Bhardwaj, Renuka Dulala, Senthil Rajappa, Chandravathi Loke
Summary: The management of breast cancers in India needs greater emphasis on awareness, early detection, standard pathologic testing, and cost-effective solutions. With standardized management, outcomes similar to those of developed countries can be expected. Additionally, clinical trials aimed at a more diverse population in LMICs like India should be undertaken.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Victoria E. Forbes, Mary D. Chamberlin, Vincent Dusabejambo, Tim Walker, Steve P. Bensen, Norrisa Haynes, Kathryn Nunes, Veauthyelau Saint-Joy, Frederick L. Makrauer
Summary: Global health education needs to adapt to the challenges we face, such as inequities and pandemics. Virtual teaching models are effective in delivering global health education and improving outcomes through bidirectional learning and equitable partnerships.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Tefta Isufaj Haliti, Ilir Hoxha, Rubena Mojsiu, Rohini Mandal, Goksu Goc, Kreshnike Dedushi Hoti
Summary: The IOTA Simple Rules have high diagnostic performance in distinguishing between benign and malignant adnexal masses, providing a reliable tool for early diagnosis of ovarian cancer.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Cecilia Felix Penido Mendes de Sousa, Jared Pasetsky, Gustavo Nader Marta, Megan Kassick, Fabio Ynoe Moraes, Luqman K. Dad
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary D. Chamberlin, Dafina Ademi Islami, Shqiptar Demaci, Richard J. Barth Jr
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Jeta Bunjaku, Arber Lama, Tawanda Pesanayi, Jeton Shatri, Mary Chamberlin, Ilir Hoxha
Summary: The evidence suggests that lifestyle factors such as alcohol and coffee intake may increase the risk of lung cancer, while tea intake may have a protective effect. However, the quality of evidence is currently low and further research is needed.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Mary Chamberlin, Christopher Booth, Gabriel A. Brooks, Achille Manirakiza, Fidel Rubagumya, Verna Vanderpuye
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Article
Oncology
Anne Christine Buteau, Alicia Castelo-Loureiro, Regina Barragan-Carrillo, Suyapa Bejarano, Alba J. Kihn-Alarcon, Enrique Soto-Perez-de-Celis
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)
Review
Oncology
Ilir Hoxha, Fitim Sadiku, Lot Hoxha, Midhet Nasim, Marie Anne Christine Buteau, Krenare Grezda, Mary D. Chamberlin
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
(2024)